Advertisement
Advertisement
UPC
Universe Pharmaceuticals Inc. Class A Ordinary Shares
5.56
USDSponsored
-0.68
-10.90%
Aug 07, 15:59 UTC -4
Closed
After-Market
5.52
-0.04
-0.72%
UPC Earnings Reports
Positive Surprise Ratio
No Data Available for UPC
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Universe Pharmaceuticals Inc. Class A Ordinary Shares earnings per share and revenue
On Jul 20, 2026, UPC reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Relay Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.41
Surprise
-2.78%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Profound Medical Corp. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
$0.26
Surprise
+199.01%
OmniAb, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.05
Surprise
+59.15%
FAQ
What were Universe Pharmaceuticals Inc. Class A Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Universe Pharmaceuticals Inc. Class A Ordinary Shares reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Universe Pharmaceuticals Inc. Class A Ordinary Shares's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Universe Pharmaceuticals Inc. Class A Ordinary Shares expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Universe Pharmaceuticals Inc. Class A Ordinary Shares's next earnings report?
Based on --
analysts, Universe Pharmaceuticals Inc. Class A Ordinary Shares is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement